Several cases of autoimmune hepatitis (AIH)-like lesions following allogeneic hematopoietic stem cell transplantation (allo-HSCT) have been reported. [1] [2] [3] [4] In general, AIH is a chronic inflammatory disorder characterized by interface hepatitis, increased Ig, autoantibody levels and a dramatic response to immunosuppression. Much evidence supports a central role of T-cell dysfunction in the pathogenesis of AIH, although autoantibodies produced by plasma cells also contribute to the pathogenesis. 5 Hepatic GvHD is one of the most important hepatic complications after allo-HSCT. It is characterized by lymphocytic cholangiolitis with apoptosis and has different pathological features from interface hepatitis of AIH. 6 Lobular hepatitis type of hepatic GvHD is proposed; however, its features are also different from AIH. 7 The incidence and clinical features of patients with AIH-like lesions following allo-HSCT is not well understood; therefore, the aim of this study is to clarify the clinical manifestations of this hepatic complication by comparing it with hepatic GvHD. We used the term 'autoimmune-like hepatitis (AILH)' to describe this hepatic disorder because this lesion is not 'autoimmune' in the setting of allo-HSCT. We investigated the liver biopsy specimens after allo-HSCT between 1991 and 2010 in our institute. This study was approved by the institutional review board of Japanese Red Cross Nagoya Daiichi Hospital and all patients provided their written, informed consent. maintained without lymphocyte infiltration or apoptosis. The histological diagnosis was made according to the International AIH scoring system. 5 Hepatic GvHD was diagnosed by the lymphocytic cholangiolitis with apoptosis. 6 The epithelial cells of small bile ducts show nuclear pleomorphism, and individual degeneration with apoptosis and intraepithelial lymphocytosis, mainly involving infiltration by CD8-positive T cells.
During this period, 635 patients underwent allo-HSCT and 66 patients received liver biopsy. The indications for liver biopsy in our center were as follows: (1) progressive elevation of liver function tests of greater than five times the upper limit of normal range; (2) the clinically apparent causes, such as infections or medications, did not exist. The patients with ascites, the patients with high risk of bleeding and the patients whose clinical conditions were extremely severe were excluded.
Five patients were diagnosed with AILH (7.3% in patients who underwent liver biopsy, 0.79% in the whole cohort), whereas 23 patients were diagnosed with hepatic GvHD (33.8% in patients who underwent liver biopsy, 3.6% in the whole cohort). The remaining patients were diagnosed with ischemic cholangiopathy, veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS), viral hepatitis, steatohepatitis, drug-induced hepatitis, hemosiderosis and other nonspecific lesions.
Patients' characteristics, onset of the hepatic complications, laboratory findings, and treatment outcomes of AILH and hepatic GvHD were summarized in Table 1 . The onset of AILH (median, 320 days; range, 133-2631 days) was significantly later than that of hepatic GvHD (median, 90; range, 29-422 days; P = 0.005). There were no significant differences in patients' background characteristics, and the incidence of acute and chronic GvHD between AILH and hepatic GvHD.
The laboratory data showed that peak AST levels were significantly higher in the AILH group than in the hepatic GvHD group (P = 0.007) and AST levels at the time of biopsy also tended to be higher in the AILH group (AILH; median 439 IU/L, range 44-860, hepatic GvHD; median 166 IU/L, range 56-501, P = 0.072). Gamma-glutamic transpeptidase (GGT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH) levels were markedly elevated in both the groups, with no significant difference (data not shown). Autoantibody screening was performed in all five patients of AILH and in eleven patients of hepatic GvHD (47.8%). Two patients with AILH were anti-smooth muscle Ab-positive, and one was both anti-mitochondrial Ab-positive and antinuclear Abpositive with a high titer (1:640). In the hepatic GvHD group, six patients were antinuclear Ab-positive (range; 1:20-1:320). One of the six patients was also anti-mitochondrial Ab-positive. No patient in the hepatic GvHD group was anti-smooth muscle Abpositive. All patients were serologically negative for hepatitis viruses, HAV, HBV and HCV. CMV and EBV were all latent infections without reactivation.
Three out of five AILH patients and 16 of 23 hepatic GvHD patients were treated with corticosteroids and dose adjustment of calcineurin inhibitors at the discretion of the physician. Patients treated without corticosteroids have received dose adjustment of calcineurin inhibitors and supportive care. Treatment response was defined as improvement of all liver function tests after the treatment and complete response (CR) was defined as normalization of all of the liver function tests. All AILH patients responded and three patients achieved CR with or without corticosteroids. Five-year overall survival after biopsy tended to be better in the AILH group (75%) than in the hepatic GvHD group (33.3%); (P = 0.07).
In this study, AILH with typical histology of interface hepatitis and lymphoplasmacytic infiltration was seen in 0.79% patients after allo-HSCT as a late complication. This complication also developed late in previously reported cases. [1] [2] [3] [4] Because our cohort included some patients whose hepatic dysfunction was too severe to perform a liver biopsy, the incidence of AILH could be somewhat inaccurate.
The majority of infiltrating cells in AILH were CD8-positive T cells that were the main effectors in GvHD, although distinct CD20-positive B cells and CD138-positive plasma cells were also observed The effector cells in AILH might be different from those in hepatic GvHD. Higher elevation in transaminase levels in the AILH group suggested that the target cells in AILH were also different from those in hepatic GvHD. Hepatocytes might be the main target in AILH. The cellular alloimmune reaction after allo-HSCT is the usual hepatic GvHD that is characterized by the apoptotic lymphocytic cholangiolitis caused by cytotoxic T cells. In contrast, pathogenesis of AILH might be the humoral alloimmune reaction, in which B cells and plasma cells were involved. In other words, AILH might be the humoral type of hepatic GvHD. In the setting of liver transplantation, graft dysfunction associated with AIH (called 'de novo AIH') has been well described. [8] [9] [10] De novo AIH after liver transplantation is characterized by the late onset such as months or years after transplantation, the good response to the corticosteroids and the lack of response to calcineurin inhibitors. The humoral immune response is presumed to participate in the pathogenesis of de novo AIH. AILH after allo-HSCT and de novo AIH after liver transplantation had several similarities such as the pathology, the onset and autoantibodies. AILH and de novo AIH might be the complications with mirror-imaged mechanisms after allotransplanation. The current concept of B-cell involvement in the pathogenesis of chronic GvHD and the efficacy of rituximab treatment for chronic GvHD confirm this idea. 11, 12 Furthermore, the previously reported patient with AILH after allo-HSCT who did not respond to corticosteroid but responded to rituximab also suggested the B-cell involvement in this complication. 4 Although the steroid refractory case of AILH was reported, all AILH cases in our cohort were improved with or without corticosteroid. This might indicate the heterogeneity of this complication or the difficulty of diagnosis. Originally, autoimmune hepatitis was diagnosed using pathological findings along with serological data, HLA and other clinical information. The diagnostic scoring system recommended by the International Autoimmune Hepatitis Group is commonly used. 5 Nevertheless, this scoring system cannot always be applied in the setting of allo-HSCT. Liver biopsy is required for definitive diagnosis; however, autoantibody testing might be informative because three out of five patients of AILH in our cohort were autoantibody-positive.
In summary, the hepatic complication with the pathological features of AIH could be seen late after allo-HSCT. Humoral alloimmune reaction was presumed to be the pathological mechanism of this complication. We suggest hepatic GvHD might be subdivided into usual type and AILH type by the clinicopathological characters.
